Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
2 2nd Session of the 60th Legislature (2026)
3 HOUSE BILL 4293 By: Pae
4
5
6 AS INTRODUCED
7 An Act relating to controlled dangerous substances;
creating the Veterans Mental Health Innovation Act;
8 authorizing certain entities to conduct scientific
research and clinical trials related to ibogaine;
9 specifying certain uses for which scientific research
or clinical trials are authorized; limiting number of
10 memoranda of agreement that universities or
institutions of higher education may enter into;
11 imposing requirements with respect to studies;
requiring registration with the State Department of
12 Health and the Oklahoma Department of Agriculture,
Food, and Forestry; prescribing requirements for
13 registration information; providing for specified
nonrefundable fees; requiring additional registration
14 with the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control; stipulating duration of
15 registration; requiring certain notification of
change of facility location; requiring written
16 certifications for clinical trial participants;
prescribing content of written certifications;
17 providing for expiration of certifications; providing
immunity to persons conducting or participating in
18 research or clinical trials; requiring submission of
written reports by certain date; providing for
19 confidentiality of certain personal information;
requiring specified agencies to maintain
20 confidentiality with respect to information;
directing promulgation of rules; providing for
21 codification; and providing an effective date.
22
23
24
Req. No. 15634 Page 1
1 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
2 SECTION 1. NEW LAW A new section of law to be codified
3 in the Oklahoma Statutes as Section 2-810 of Title 63, unless there
4 is created a duplication in numbering, reads as follows:
5 A. This act shall be known and may be cited as the "Veterans
6 Mental Health Innovation Act".
7 B. The purpose of this act is to allow states and commonwealths
8 to join a multistate consortium to advance research on ibogaine as
9 medical treatment.
10 SECTION 2. NEW LAW A new section of law to be codified
11 in the Oklahoma Statutes as Section 2-811 of Title 63, unless there
12 is created a duplication in numbering, reads as follows:
13 A. A university or other institution of higher education
14 located in this state, or a research facility that has entered into
15 a memorandum of agreement with a university or institution of higher
16 education located in this state, may conduct scientific research on
17 ibogaine for the treatment of persons eighteen (18) years of age or
18 older who experience any of the following medical conditions:
19 1. Posttraumatic stress disorder;
20 2. Treatment-resistant/refractory depression;
21 3. Treatment-resistant/refractory anxiety;
22 4. Treatment-resistant/refractory obsessive-compulsive
23 disorder;
24 5. Traumatic brain injury;
Req. No. 15634 Page 2
1 6. Early-stage dementia;
2 7. Palliative care;
3 8. End-of-life care;
4 9. Opioid use disorder; or
5 10. Moderate to severe chronic pain.
6 B. The university or institution of higher education may enter
7 into no more than one memorandum of agreement with a research
8 facility for the purposes of conducting scientific research under
9 this section.
10 C. In conducting such scientific research as described in
11 subsection B of this section, the studies shall:
12 1. Study the therapeutic efficacy of using ibogaine in the
13 treatment of the medical conditions listed in subsection B of this
14 section;
15 2. Review the current literature regarding:
16 a. the safety and efficacy of using ibogaine in the
17 treatment of the medical conditions listed in
18 subsection C of this section, and
19 b. the access persons have to ibogaine for the treatment
20 of the medical conditions listed in subsection A of
21 this section; and
22 3. Examine the science of cultivation, synthesis, extraction,
23 and processing of ibogaine as well as any other naturally occurring
24 source organisms of these molecules.
Req. No. 15634 Page 3
1 D. 1. Eligible entities as described in subsection A of this
2 section shall register with the State Department of Health and the
3 Oklahoma Department of Agriculture, Food, and Forestry prior to and
4 for the purposes of growing, studying, processing, or dispensing
5 ibogaine-containing Tabernanthe iboga plant, or studying,
6 extracting, synthesizing, or dispensing ibogaine. The registration
7 submission information shall include:
8 a. the name and address of the research facility,
9 b. a prospectus approved by a university or other
10 institution of higher education, and
11 c. certification from the institutional review board of
12 the university or institution of higher education if
13 human trials are part of the research.
14 2. By registering, the registrant acknowledges and agrees that:
15 a. the information contained in the registration
16 submissions may be provided to law enforcement
17 agencies, and
18 b. the registrant shall submit an annual report detailing
19 compliance with annual regulation requirements.
20 3. The State Department of Health shall collect a one-time,
21 nonrefundable fee of Five Hundred Dollars ($500.00) from the
22 registrant at the time of registration and the Oklahoma Department
23 of Agriculture, Food, and Forestry shall collect a one-time
24 nonrefundable fee of One Hundred Dollars ($100.00) from the
Req. No. 15634 Page 4
1 registrant at the time of registration. The registrant shall, upon
2 completion of registration with the State Department of Health and
3 the Oklahoma Department of Agriculture, Food, and Forestry, register
4 with the Oklahoma State Bureau of Narcotics and Dangerous Drugs
5 Control as provided by Section 2-301 et seq. of Title 63 of the
6 Oklahoma Statutes annually for as long as the research remains
7 active.
8 4. Registration under this subsection is valid for one (1)
9 year, effective upon confirmation and receipt of all registrations
10 required by this subsection. Notwithstanding the registration fee
11 listed in Section 2-303 of Title 63 of the Oklahoma Statutes, the
12 registration required by this subsection shall satisfy and supersede
13 all other registration and reporting requirements otherwise imposed
14 by state law.
15 5. Should the registrant change facility locations for the
16 cultivation, testing, synthesis, storage, or dispensing of ibogaine,
17 it shall report such changes within fourteen (14) business days to
18 the State Department of Health, the Oklahoma Department of
19 Agriculture, Food, and Forestry, and the Oklahoma State Bureau of
20 Narcotics and Dangerous Drugs Control.
21 E. 1. A written certification shall be issued to persons
22 qualifying for participation in the pilot program described in this
23 section by a physician participating in the pilot program. The
24 written certification shall contain the following:
Req. No. 15634 Page 5
1 a. the name, address, and telephone number of the issuing
2 physician,
3 b. the name and address of the patient to whom the
4 written certification is issued,
5 c. the date on which the written certification was made,
6 d. the signature of the physician,
7 e. the quantity of ibogaine to be dispensed, and
8 f. the form of ibogaine to be dispensed.
9 2. The written certification issued under this subsection shall
10 expire one (1) year after its issuance unless the written
11 certification specifies an earlier date of expiration.
12 F. 1. A scientific researcher or physician operating under a
13 valid registration issued in accordance with this section shall not
14 be subject to arrest, prosecution, or any civil or administrative
15 penalty for the possession, cultivation, synthesis, extraction, or
16 distribution of ibogaine insofar as the scientific researcher's or
17 physician's conduct is in compliance with the provisions of this
18 section.
19 2. A patient participating in the pilot program under a valid
20 written certification issued in accordance with this section shall
21 not be subject to arrest, prosecution, or any civil or
22 administrative penalty for the use or possession of ibogaine insofar
23 as the patient's conduct is in compliance with the provisions of
24 this section.
Req. No. 15634 Page 6
1 3. In any prosecution involving possession of ibogaine as those
2 terms are specified in subsection C of Section 2-204 of Title 63 of
3 the Oklahoma Statutes, it shall be an affirmative defense if a
4 person can demonstrate by clear and convincing evidence that he or
5 she has one or more of the qualifying medical conditions or
6 circumstances listed in subsection B of this section. This
7 subsection shall not be understood to be the decriminalization of
8 ibogaine.
9 G. Researching entities shall submit a final written report to
10 the President Pro Tempore of the Oklahoma State Senate and the
11 Speaker of the Oklahoma House of Representatives containing the
12 results of the studies conducted under this section and any
13 recommendations for legislative or other actions not later than
14 December 1, 2029.
15 H. Researching entities shall ensure any protected health
16 information collected during the pilot program done in accordance
17 with this section does not personally identify any individual.
18 I. The State Department of Health, the Oklahoma Department of
19 Agriculture, Food, and Forestry, the Oklahoma State Bureau of
20 Narcotics and Dangerous Drugs Control, and any other state agency
21 with access to the research programs authorized by this section
22 shall not release or allow to be released through inaction any
23 protected health information. The protected health information of
24
Req. No. 15634 Page 7
1 pilot program participants shall be exempt from the Oklahoma Open
2 Records Act.
3 J. The State Commissioner of Health, the State Board of
4 Agriculture, and the Director of the Oklahoma State Bureau of
5 Narcotics and Dangerous Drugs Control shall promulgate rules
6 necessary to implement the program authorized in this section.
7 K. On the condition that ibogaine is approved by the Untied
8 States Food and Drug Administration to treat a medical condition:
9 1. A licensed physician shall prescribe ibogaine for a patient;
10 and
11 2. A licensed physician shall supervise the administration of
12 ibogaine at a hospital or other licensed health care facility to
13 ensure the patient's safety while the patient is under the influence
14 of ibogaine.
15 SECTION 3. This act shall become effective November 1, 2026.
16
17 60-2-15634 TKR 01/12/26
18
19
20
21
22
23
24
Req. No. 15634 Page 8Every fact on this page links to its source, starting with the official bill record.